LakshmiNRajdevMD

Oncology • New York, NY

Assistant Professor, Medicine, A Einstein College of Medicine of Yeshiva Univ

Join to view full profile

Dr. Rajdev is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rajdev's full profile

Already have an account?

Office
100 East 77th Street
New York, NY 10075
Phone+1 212-434-2675

Fax+1 718-405-8433

Education & Training

NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1995 - 1997
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1994 - 1995
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1991 - 1994
Grant Medical CollegeClass of 1987

Certifications & Licensure

NY State Medical License 1994 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer Start of enrollment: 2005 Jun 03
Completed
Phase 1, Phase 2
OSI-774 (Erlotinib, Tarceva) in Elderly Patients Start of enrollment: 2003 Jul 02
Completed
Phase 2
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Adjuvant Aflibercept for Metastatic Colorectal Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer Start of enrollment: 2012 May 01
Completed
Phase 1, Phase 2
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer Start of enrollment: 2013 Apr 01
Terminated
Phase 1, Phase 2
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Start of enrollment: 2017 Apr 28
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.
Van K Morris, Erin B Kennedy, Manik A Amin, Olivia Aranha, Al B Benson 3rd
Journal of Clinical Oncology. 2024-12-16
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set.
Robert Samuel, Stephen R Knight, Richard Adams, Prajnan Das, Jennifer Dorth
Eclinicalmedicine. 2024-12-01
9 citations
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
Lakshmi Rajdev, Chia-Ching Jackie Wang, Himanshu Joshi, Shelly Lensing, Jeannette Lee
Cancer. 2024-03-15

Lectures

AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in H...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Hindi